Virchows Archiv

, Volume 430, Issue 1, pp 23–28 | Cite as

E-Cadherin (E-cad) expression in duct carcinoma in situ (DCIS) of the breast

  • S. K. Gupta
  • A. G. Douglas-Jones
  • B. Jasani
  • J. M. Morgan
  • M. Pignatelli
  • R. E. Mansel
Original Article

Abstract

E-cadherin (E-cad) is an epithelial cell-cell adhesion molecule whose loss or reduced expression is associated with a more invasive tumour phenotype. Ninety-six cases of screen detected pure ductal carcinoma in situ (DCIS) were analysed immunocytochemically for expression of E-cad using the HECD-1 mouse monoclonal antibody. The in situ component in each case was classified on the basis of cytonuclear grade, extent of necrosis, Van Nuys classification and a newly devised Cardiff classification. The amount of E-cad expression was assessed semi-quantitatively using an intensity distribution method. There is significantly more expression of E-cad in well-differentiated DCIS when compared with poorly differentiated DCIS and this finding is highly significant (P<0.001) irrespective of the classification system used. These findings suggest that progressive loss of E-cad expression may occur at an early stage of breast cancer development.

Key words

Adhesion molecules E-cadherin Duct carcinoma of breast Breast 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Holler H (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54:3845–3852Google Scholar
  2. 2.
    Bringuier PP, Umbas R, Schaafsma HE, Karthaus HE, Oosterhof GO, Debruyne FM, Schalken JA (1993) Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumours. Cancer Res 53:3241–3245Google Scholar
  3. 3.
    Bussemakers MJ, Giroldi LA, van Bokhoven A, Schalken JA (1994) Transcriptional regulation of the human E-cadherin gene promoter. Biochem Biophys Res Commun 203:1284–1290Google Scholar
  4. 4.
    Douglas-Jones AG, Schmid KW, Bier B, Horgan K, Lyons K, Dallimore ND, Moneypenny I, Jasani B (1995) Metallothionein expression in duct carcinoma in situ of the breast. Human Pathol 26:217–222Google Scholar
  5. 5.
    Douglas-Jones AG, Gupta SK, Attanoos RL, Morgan JM, Mansel RE (1996) A critical appraisal of six modern classifications of duct carcinoma in situ: correlation with grade of the invasive carcinoma. Histopathology 29:397–410Google Scholar
  6. 6.
    Gagliardi G, Kandemir O, Liu D, Guida M, Benvestito S, Ruers TG, Benjamin IS, Northover JM, Stamp GW, Talbot IC (1995) Changes in E-cadherin immunoreactivity in the adenoma-carcinoma sequence of the large bowel. Virchows Arch 426:149–154Google Scholar
  7. 7.
    Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, Cano A (1993) Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 142:987–993Google Scholar
  8. 8.
    Gupta SK, Douglas-Jones AG, Morgan JM, Mansel RE (1996) A new histological classification (Cardiff classification) of ductal carcinoma in situ (DCIS) of the breast with prognostic implications. J Pathol (abstract in press)Google Scholar
  9. 9.
    Holland R, Peterse JL, Millis RR, Eusebi V, Faverley D, van de Vijver MJ, Zafrani B (1994) Ductal carcinoma in situ: a proposal for a new classification. Semin Diag Pathol 11:167–180Google Scholar
  10. 10.
    Jiang WG (1996) E-cadherin and its associated protein catenins, cancer invasion and metastases. Brit J Surg 83:437–446Google Scholar
  11. 11.
    Lipponen P, Saarelainen E, Ji H, Aaltomaa S, Syrjanen K (1994) Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer. J Pathol 174:101–109Google Scholar
  12. 12.
    McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS (1985) Oestrogen receptor analysis: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109:716–721Google Scholar
  13. 13.
    Menger MD, Vollmar B (1996) Adhesion molecules as determinants of disease: from molecular biology to surgical research. Brit J Surg 83:588–601Google Scholar
  14. 14.
    Moll R, Mitze M, Frixen UH, Birchmeier W (1993) Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 143:1731–1742Google Scholar
  15. 15.
    Nagafuchi A, Shirayoshi Y, Okazaki K, Yasuda K, Takeichi M (1987) Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA. Nature 329:341–343Google Scholar
  16. 16.
    Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahare H, Kobayashi T, Takatsuka Y, Matsuyoshi N, Hirano S, Takeichi M (1993) Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastases. Cancer Res 53:1696–1701Google Scholar
  17. 17.
    Palacios J, Benito N, Pizarro A, Suarez A, Espada J, Cano A, Gamallo C (1995) Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. Am J Pathol 146:605–612Google Scholar
  18. 18.
    Poller DN, Ellis IO (1995) Ductal carcinoma in situ (DCIS) of the breast. In: Kirkham N, Lemoine N R (eds) Progress in Pathology, vol. 2. Churchill Livingstone, Edinburgh, pp 47–87Google Scholar
  19. 19.
    Sakuragi N, Nishiya M, Ikeda K, Ohkouch T, Furth EE, Hareyama H, Satoh C, Fujimoto S (1994) Decreased E-cadherin expression in endometrial carcinoma is associated with tumour dedifferentiation and deep myometrial invasion. Gynecol Oncol 53:183–189Google Scholar
  20. 20.
    Shimoyama Y, Hirohashi S, Hirano S, Noguchi M, Shimosato Y, Takeichi M, Abe O (1989) Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. Cancer Res 49:2128–2133Google Scholar
  21. 21.
    Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, Iihara K, Doki Y, Hirano S, Takeichi M (1991) Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol 139:17–23Google Scholar
  22. 22.
    Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ (1996) Reduced E-Cadherin expression is associated with invasiveness and unfavourable prognosis in breast cancer. Am J Clin Pathol 105:394–402Google Scholar
  23. 23.
    Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, Lewinsky B, Gamagami P, Slamon DJ (1995) Prognostic classification of breast ductal carcinoma in situ. Lancet 345:1154–1157Google Scholar
  24. 24.
    Slagle BL, Zhou YZ, Birchmeier W, Scorsone KA (1993) Deletion of the E-cadherin gene in hepatitis B virus-positive Chinese hepatocellular carcinomas. Hepatology 18:757–762Google Scholar
  25. 25.
    Takayama T, Shiozaki H, Inoue M, Oka H, Tamura S, Takatsuka Y, Mori T (1994) Expression of E-cadherin and alpha catenin molecules in human breast cancer tissues and association with clinicopathological features. International J Oncol 5: 775–780Google Scholar
  26. 26.
    Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA (1994) Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54:3929–3933Google Scholar
  27. 27.
    Vandewalle B, Revillion F, Doutrelant P, Granier AM, Lefebvre J (1994) Effects of calcium on E-cadherin expression in breast tumour cells. Int J Oncol 4:181–185Google Scholar
  28. 28.
    van Dongen JA, Holland R, Peterse JL, Fentiman IS, Lagios MD, Millis RR, Recht A (1992) Ductal carcinoma in situ of the breast: Second EORTC Consensus Meeting. Eur J Cancer 28:626–629Google Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • S. K. Gupta
    • 1
  • A. G. Douglas-Jones
    • 2
  • B. Jasani
    • 2
  • J. M. Morgan
    • 2
  • M. Pignatelli
    • 3
  • R. E. Mansel
    • 1
  1. 1.Department of SurgeryUniversity of Wales College of MedicineCardiffUK
  2. 2.Department of PathologyUniversity of Wales College of MedicineCardiffUK
  3. 3.Department of Histopathology, Royal Postgraduate Medical SchoolHammersmith HospitalLondonUK

Personalised recommendations